Issues
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Articles
Absence of PTEN/MMAC1 Germ-Line Mutations in Sporadic Bannayan-Riley-Ruvalcaba Syndrome1
Type I Transforming Growth Factor β Receptor Maps to 9q22 and Exhibits a Polymorphism and a Rare Variant within a Polyalanine Tract1
Squalamine Inhibits Angiogenesis and Solid Tumor Growth in Vivo and Perturbs Embryonic Vasculature1
Phase I Trial of Intraperitoneal Iododeoxyuridine with and without Intravenous High-Dose Folinic Acid in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity: Flow Cytometric and Pharmacokinetic Analysis1
Effective Adoptive Immunotherapy by T-LAK Cells Retargeted with Bacterial Superantigen-conjugated Antibody to MUC1 in Xenografted Severe Combined Immunodeficient Mice1
Progression of Hepatic Neoplasms Is Severely Retarded in Mice Lacking the Bisecting N-Acetylglucosamine on N-Glycans: Evidence for a Glycoprotein Factor that Facilitates Hepatic Tumor Progression1
p53 Genes Mutated in the DNA Binding Site or at a Specific COOH-terminal Site Exert Divergent Effects on Thyroid Cell Growth and Differentiation1
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds